JP2014523920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523920A5 JP2014523920A5 JP2014522119A JP2014522119A JP2014523920A5 JP 2014523920 A5 JP2014523920 A5 JP 2014523920A5 JP 2014522119 A JP2014522119 A JP 2014522119A JP 2014522119 A JP2014522119 A JP 2014522119A JP 2014523920 A5 JP2014523920 A5 JP 2014523920A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- cxcr4
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 41
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 41
- 239000012634 fragment Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 17
- 239000012472 biological sample Substances 0.000 claims 10
- 238000000338 in vitro Methods 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000009257 reactivity Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 231100000588 tumorigenic Toxicity 0.000 claims 3
- 230000000381 tumorigenic effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- -1 The antibody Substances 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513345P | 2011-07-29 | 2011-07-29 | |
| US61/513,345 | 2011-07-29 | ||
| EP11306000.8 | 2011-07-29 | ||
| EP11306000 | 2011-07-29 | ||
| PCT/EP2012/064876 WO2013017562A1 (en) | 2011-07-29 | 2012-07-30 | Use of the antibody i-3859 for the detection and diagnosis of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523920A JP2014523920A (ja) | 2014-09-18 |
| JP2014523920A5 true JP2014523920A5 (enExample) | 2015-08-20 |
| JP6138780B2 JP6138780B2 (ja) | 2017-05-31 |
Family
ID=47628653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014522119A Expired - Fee Related JP6138780B2 (ja) | 2011-07-29 | 2012-07-30 | 癌の検出および診断のための抗体ｉ−３８５９の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140170677A1 (enExample) |
| EP (1) | EP2736926A1 (enExample) |
| JP (1) | JP6138780B2 (enExample) |
| KR (1) | KR20140047127A (enExample) |
| CN (1) | CN103717620A (enExample) |
| AR (1) | AR087363A1 (enExample) |
| AU (2) | AU2012292116A1 (enExample) |
| BR (1) | BR112014001979A2 (enExample) |
| CA (1) | CA2842552A1 (enExample) |
| IL (1) | IL230693A0 (enExample) |
| MX (1) | MX2014001160A (enExample) |
| RU (1) | RU2636032C2 (enExample) |
| WO (1) | WO2013017562A1 (enExample) |
| ZA (1) | ZA201400500B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3316159A4 (en) | 2015-06-25 | 2019-08-14 | Advanced Telecommunications Research Institute International | PREDICTIVE EQUIPMENT BASED ON A SYSTEM ASSOCIATED WITH SEVERAL INSTITUTIONS AND PREDICTION PROGRAM |
| EP3365682B1 (en) * | 2015-10-23 | 2020-10-07 | Novartis AG | System for deriving cell-to-cell spatial proximities |
| US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN114594268A (zh) | 2016-03-29 | 2022-06-07 | 无限生物制药公司 | 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法 |
| EP3466446B1 (en) | 2016-03-29 | 2023-12-27 | Karydo Therapeutix, Inc. | Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| CN111465613A (zh) * | 2017-11-07 | 2020-07-28 | X4 制药有限公司 | 癌症生物标志物及其使用方法 |
| US20210025895A1 (en) * | 2018-04-13 | 2021-01-28 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
| WO2021183650A1 (en) | 2020-03-10 | 2021-09-16 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766675B2 (en) * | 1998-03-30 | 2003-10-23 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| JP2003532683A (ja) | 2000-05-09 | 2003-11-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 造血細胞のｃｘｃｒ４アンタゴニスト治療 |
| AU2001275339A1 (en) | 2000-06-05 | 2001-12-17 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| AU2003232253A1 (en) * | 2003-05-02 | 2004-11-23 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| US8329178B2 (en) * | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP2486941B1 (en) * | 2006-10-02 | 2017-03-15 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind CXCR4 and uses thereof |
| EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
-
2012
- 2012-07-27 AR ARP120102745A patent/AR087363A1/es unknown
- 2012-07-30 BR BR112014001979A patent/BR112014001979A2/pt not_active IP Right Cessation
- 2012-07-30 KR KR1020147003605A patent/KR20140047127A/ko not_active Ceased
- 2012-07-30 CA CA2842552A patent/CA2842552A1/en not_active Abandoned
- 2012-07-30 RU RU2014103054A patent/RU2636032C2/ru not_active IP Right Cessation
- 2012-07-30 JP JP2014522119A patent/JP6138780B2/ja not_active Expired - Fee Related
- 2012-07-30 MX MX2014001160A patent/MX2014001160A/es unknown
- 2012-07-30 AU AU2012292116A patent/AU2012292116A1/en not_active Abandoned
- 2012-07-30 WO PCT/EP2012/064876 patent/WO2013017562A1/en not_active Ceased
- 2012-07-30 US US14/235,235 patent/US20140170677A1/en not_active Abandoned
- 2012-07-30 EP EP12740374.9A patent/EP2736926A1/en not_active Ceased
- 2012-07-30 CN CN201280037703.0A patent/CN103717620A/zh active Pending
-
2014
- 2014-01-22 ZA ZA2014/00500A patent/ZA201400500B/en unknown
- 2014-01-28 IL IL230693A patent/IL230693A0/en unknown
-
2017
- 2017-06-15 AU AU2017204043A patent/AU2017204043A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523920A5 (enExample) | ||
| JP2025029025A (ja) | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法 | |
| RU2014103054A (ru) | Применение антитела i-3859 для выявления и диагностики рака | |
| JP2018519508A5 (enExample) | ||
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP2014512812A5 (enExample) | ||
| JP2018508462A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| JP2013539468A5 (enExample) | ||
| WO2017210631A1 (en) | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer | |
| US20230088070A1 (en) | Use of il-1beta binding antibodies | |
| JP2015523852A5 (enExample) | ||
| RU2014145633A (ru) | Композиции и способы для диагностики и лечения опухолей | |
| RU2017136863A (ru) | Способы лечения рака легкого | |
| JP2018516244A5 (enExample) | ||
| AU2017311585A1 (en) | Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor | |
| JP2014515740A5 (enExample) | ||
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| JP2018516877A5 (enExample) | ||
| RU2017140467A (ru) | Антитело к igf-1r и его применение для диагностики рака | |
| JP6351828B2 (ja) | 肝細胞癌の抗ｖｅｇｆｒ２抗体治療 | |
| RU2017140464A (ru) | Антитело к igf-1r и его применение для диагностики рака | |
| JP7526793B2 (ja) | ヒト化抗ｃａ ｉｘ抗体、およびその使用方法 | |
| Testi et al. | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives | |
| EP4687977A2 (en) | Methods of treating melanoma using an anti-ctla4 antibody |